The effect of donor age on penetrating keratoplasty for endothelial disease: Graft survival after 10 years in the cornea donor study

Mark J. Mannis, University of California, Davis
Edward J Holland, Cincinnati Eye Institute
Robin L. Gal, Jaeb Center for Health Research
Mariya Dontchev, Jaeb Center for Health Research
Craig Kollman, Jaeb Center for Health Research
Dan Raghinaru, Jaeb Center for Health Research
Steven P. Dunn, Michigan Cornea Consultants
Robert L. Schultze, Cornea Consultants of Albany
David D. Verdier, Verdier Eye Center
Jonathan H. Lass, University Hospitals Eye Institute

Only first 10 authors above; see publication for full author list.

Journal Title: Ophthalmology (Section 12 EMBASE)
Volume: Volume 120, Number 12
Publisher: Elsevier | 2013-12-01, Pages 2419-2427
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.ophtha.2013.08.026
Permanent URL: https://pid.emory.edu/ark:/25593/twd4d

Final published version: http://dx.doi.org/10.1016/j.ophtha.2013.08.026

Copyright information:
© 2013 by the American Academy of Ophthalmology Published by Elsevier Inc.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed November 27, 2019 11:56 PM EST
The Effect of Donor Age on Penetrating Keratoplasty for Endothelial Disease: Graft Survival after 10 Years in the Cornea Donor Study

Mark J. Mannis, MD, Edward J Holland, MD, Robin L. Gal, MSPH, Mariya Dontchev, MPH, Craig Kollman, PhD, Dan Raghinaru, MS, Steven P. Dunn, MD, Robert L. Schultze, MD, David D. Verdier, MD, Jonathan H. Lass, MD, Irving M. Raber, MD, Joel Sugar, MD, Mark S. Gorovoy, MD, Alan Sugar, MD, R. Doyle Stulting, MD, PhD, Monty M. Montoya, MBA, Jeffrey G. Penta, MBA, Beth Ann Benetz, Roy W. Beck, MD, PhD, and The Writing Committee for the Cornea Donor Study Research Group

1 University of California Davis, Sacramento, CA
2 Cincinnati Eye Institute, Department of Ophthalmology and Visual Sciences, Cincinnati, OH
3 Jaeb Center for Health Research, Tampa, FL
4 Michigan Cornea Consultants, P.C., Southfield, MI
5 Cornea Consultants of Albany, Albany, NY
6 Verdier Eye Center, Grand Rapids, MI
7 Case Western Reserve University and University Hospitals Eye Institute, Cleveland, OH
8 Ophthalmic Partners of Pennsylvania, Bala Cynwyd, PA
9 University of Illinois at Chicago, Chicago, IL
10 Gorovoy Eye Specialists, Ft. Meyers, FL
11 W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI
12 Emory University (now at Woolfson Eye Institute), Atlanta, GA
13 SightLife, Seattle, WA
14 San Diego Eye Bank, San Diego, CA

Abstract
Objective—To determine whether the 10-year success rate of penetrating keratoplasty for corneal endothelial disorders is associated with donor age.

Design—Multi-center, prospective, double-masked clinical trial

Participants—1090 participants undergoing penetrating keratoplasty at 80 sites for Fuchs’ dystrophy (62%), pseudophakic/aphakic corneal edema (34%) or another corneal endothelial disorder (4%) and followed for up to 12 years.

Methods—Forty-three eye banks provided corneas from donors 12 to 75 years old, using a randomized approach to assign donor corneas to study participants, without respect to recipient factors. Surgery and postoperative care were performed according to the surgeons’ usual routines.

Main Outcome Measure—Graft failure defined as a regraft or in the absence of a regraft, a cloudy cornea that was sufficiently opaque to compromise vision for 3 consecutive months.

Results—In the primary analysis, the 10-year success rate was 77% for 707 corneas from donors 12 to 65 years old compared with 71% for 383 donors 66 to 75 years old (difference = +6%, 95% confidence interval = −1% to +12%, P=0.11). When analyzed as a continuous variable, higher donor age was associated with lower graft success after the first 5 years (P<0.001). Exploring this association further, we observed that the 10-year success rate was relatively constant for donors 34 to 71 years old (75%). The success rate was higher for 80 donors 12 to 33 (96%) and lower for 130 donors 72 to 75 years old (62%). The relative drop in the success rate with donor ages 72 to 75 years was not observed until after year 6.

Conclusions—Although the primary analysis did not show a significant difference in 10-year success rates comparing donor ages 12 to 65 and 66 to 75 years, there was evidence of a donor age effect at the extremes of the age range. Since we observed a fairly constant 10-year success rate for donors age 34 to 71 years, which account for approximately 75% of corneas in the United States available for transplant, the Cornea Donor Study results indicate that donor age is not an important factor in most penetrating keratoplasties for endothelial disease.

INTRODUCTION

In 2012, more than 46,000 cornea transplants were performed in the United States. Although there is a sufficient supply of donor corneas to fulfill current domestic needs, increasing regulatory requirements pertaining to donor testing may limit the supply of available tissue. Analysis of United States statistics from 2005–2011 confirms significant increases in the percent of recovered tissue that is excluded from transplantation due to positive donor serological test results, donor medical-social histories, and slit lamp exams. Moreover, there remains a significant shortage of donor tissue internationally, with just over 19,000 corneas distributed by Eye Bank Association of America (EBAA) member eye banks for international use in 2012. Another potential challenge to the donor supply has been the transition from penetrating keratoplasty to endothelial keratoplasty for patients with endothelial disease, which has resulted in an increase in the number of patients having transplant surgery. EBAA statistics indicate that the number of endothelial keratoplasties in the United States increased from 1398 in 2005 to 24,277 in 2012. For these reasons, there is a continued need to expand the cornea donor pool worldwide. Currently, approximately half of all cornea donors are over the age of 60, and this number is likely to increase as the older population in the United States continues to expand. Widespread utilization of older donor tissue could expand the donor pool.

The Cornea Donor Study (CDS) was initiated in 2000 to provide the requisite data needed by eye banks and surgeons to evaluate whether corneas from older donors would produce the same outcomes as tissue from younger donors after corneal transplantation for cornéal endothelial conditions considered to be at moderate risk for failure, primarily Fuchs’
dystrophy and pseudophakic corneal edema. Although some of the factors that can limit the available donor pool differ now compared with 2000, the objective of the study with respect to donor age remains important. The CDS 5-year outcome data published in 2008 demonstrated that the 5-year cumulative probability of graft survival was 86% in both the 12 to 65 and the 66 to 75 year old donor age groups and there was no significant association between donor age and outcome. In addition, the distribution of causes of graft failure did not differ between the two donor age groups. The Specular Microscopy Ancillary Study (SMAS), which included 347 of the original cohort followed for five years without graft failure, found that there was a substantial decrease in endothelial cell density (ECD) from baseline for all donor ages. There was a weak negative association between ECD and donor age. Among eyes with a clear graft at 5 years, those in which the cornea was from a donor 12 to 65 years old experienced a median cell loss of 69%, resulting in a 5-year median ECD of 824 cells/mm², whereas eyes receiving a cornea from a donor 66 to 75 years old experienced a cell loss of 75%, resulting in a median 5-year ECD of 654 cells/mm². This finding of a slightly greater cell loss with older donors raised the question as to whether graft success would remain unassociated with donor age over longer-term follow up.

To determine whether the results obtained after 5 years, showing no meaningful effect of donor age on graft success, would be sustained, observation of the CDS cohort was continued. Herein, we report the CDS results over 11 years of follow up. ECD outcomes are reported separately.

METHODS

The CDS is registered as a clinical trial through the Clinical Trials Registry of the National Institutes of Health (NCT00006411) and information is publically available (http://www.clinicaltrials.gov, accessed 05/16/13). The protocol was approved by institutional review boards for all investigational sites. Each participant gave written informed consent to participate in the study, which was initially planned for 5 years of follow up. Follow up was extended, and participants without a regraft were re-consented after five years to continue follow up through December 31, 2012, which allowed for potential follow up of 10 to 12 years depending on the time of penetrating keratoplasty during study enrollment. Study methods have been detailed in prior publications and are briefly described here.

Between January 2000 and August 2002, 80 clinical sites enrolled 1,090 eligible participants whose median age at time of surgery was 72 years (interquartile range 65 to 76 years); 697 (64%) were female and 1,011 (93%) were Caucasian. The primary indication for transplant was Fuchs’ dystrophy in 676 (62%), pseudophakic or aphakic corneal edema in 369 (34%) and another corneal condition in 45 (4%) eyes. 383 (35%) study eyes received a cornea from a donor 66 to 75 years old and 707 (65%) from a donor 12 to 65 years old. Participant characteristics and donor cornea slit lamp characteristics and procurement factors were similar in the older and younger donor age groups.

At 43 eye banks, donor corneas were procured and evaluated according to the standard procedures of each eye bank, including assessment of ECD by specular microscopy. Corneas were from donors 12 to 75 years old (a range investigators found acceptable given that they were masked to donor age), with a median ECD of 2666 cells/mm² (interquartile range 2462 to 2872 cells/mm²) measured by the eye banks. The donor corneas were assigned to study participants using a randomization procedure without respect to recipient age or other participant characteristics. Clinical investigators and participants were masked to all characteristics of the donor cornea including donor age and ECD while the participant was still active in the study. Preoperative management, surgical technique, and postoperative
care, including prescription of medications, were provided according to each investigator’s customary routine.

Of the 765 living participants eligible for follow up after the first 5 years (no graft failure, choroidal hemorrhage, or trauma; and not withdrawn or lost to follow up), 663 (87%) consented to continuation of annual study visits through December 31, 2012. Additional visits were at the discretion of the investigator.

**Graft Failure**

The primary study outcome was graft survival, meaning that criteria were not met for graft failure. The criteria for graft failure, based on the definition used in Collaborative Corneal Transplantation Studies (CCTS), was a regraft or, in the absence of regraft, a cloudy cornea in which there was loss of central graft clarity sufficient to compromise vision for a minimum of three consecutive months. Cases also were considered to be graft failures when the cornea was cloudy at the last visit and there was no further follow up. Treatment of a graft which became cloudy and/or had signs of allograft rejection was administered according to each investigator’s usual routine. The date of graft failure was the date of the first examination at which the cornea was cloudy as part of the failure event. For cases in which the cornea was not documented to be cloudy prior to regraft, the date of regraft was considered to be the failure date.

Eyes were not considered to be graft failures if there was a serious operative complication such as an expulsive choroidal hemorrhage or major postoperative trauma that required surgical intervention. The data for these eyes were censored at the time of surgery or the last completed visit prior to the trauma.

Graft rejection episodes were classified as definite when an endothelial rejection line was present in a previously clear graft and probable when there was inflammation (stromal infiltrate, keratic precipitates, cells in the anterior chamber, or ciliary injection) without an endothelial rejection line in a previously clear graft.

The primary cause of graft failure was classified as one of the following: (1) primary donor failure when the graft was cloudy on the first postoperative day and did not clear within two months, (2) graft rejection when an allograft reaction occurred that, in the investigator’s judgment, was the primary reason for graft failure, (3) refractive when a regraft was performed for this indication in a clear cornea, and (4) non-rejection when not classified in either of the other three categories. The primary reason for a non-rejection failure was classified as one of the following: endothelial decompensation, infection, epithelial defect, epithelial downgrowth, wound dehiscence, hypotony, corneal thinning, glaucoma, or another cause. Glaucoma was only considered to be the primary cause when a surgical procedure was performed for glaucoma.

**Statistical Methods**

Analyses paralleled those reported after 5 years. Cumulative probabilities of graft survival (subsequently referred to as “graft survival rates or success rates”) along with pointwise 95% confidence intervals were calculated using the Kaplan-Meier method at 10 and 11 years for the two pre-specified primary donor age groups (12 to 65 years and 66 to 75 years). The log-rank test was used to assess whether there was a difference in the graft survival rates between different donor age groups. Post-hoc analyses were replicated in three data-derived (not pre-specified) donor age groups (12 to 33, 34 to 71, and 72 to 75 years) following an inspection of graft outcomes across the entire donor age distribution, which showed relatively constant success rates within each of the three age ranges. The proportional
hazards model was used to assess the relationship between graft survival and donor age analyzed as a continuous variable. Because the proportional hazards assumption was invalid for donor age, separate hazard ratios were estimated for the first five years following surgery versus years 5–12. All reported p-values are two-sided. Statistical analyses were conducted using SAS version 9.3 software (SAS Institute Inc., Cary, NC).

RESULTS

Overall, among the 1,090 participants, 224 (21%) experienced graft failure; 207 (19%) died prior to the end of the study; 21 (2%) had data censored due to operative choroidal hemorrhage or penetrating ocular trauma; 445 (41%) completed ≥10 years of follow up without graft failure; and 193 (18%) without graft failure or known death completed less than 10 years of follow up (Figure 1). Compared with participants who completed the study without graft failure, the participants who died, were lost to follow up, or withdrew (including those who declined continued participation after 5 years) were older at baseline (73 years versus 67 years), more likely to be male (40% versus 34%), and similar in race (93% versus 95% white). Among the 866 participants who did not have a graft failure, the median follow-up time was 9.7 years (interquartile range = 5.0 to 11.1 years).

Graft Outcome

Among the 224 cases with graft failure, a regraft was performed in 177 (79%) cases, while the other 47 (21%) cases met the cloudy cornea failure criteria without a regraft as of the study closure date (8 of the 47 had a cloudy cornea at the last examination without 3 months of documented cloudiness). The overall 10-year cumulative probability of graft success was 75%. While at 5 years there was no difference in graft success rates comparing the 66 to 75 and 12 to 65 year old donor age groups (N= 383 and 707, respectively), with longer follow up the survival curves of these two donor age groups separated slightly (Figure 2) although they were not significantly different (P=0.26). The 10-year cumulative probability of success was 77% for donors 12 to 65 years old compared with 71% for donors 66 to 75 years old (difference = +6%, 95% confidence interval = −1% to +12%, P=0.11). At 11 years post-transplant, the group difference was similar (difference = +5%, 95% confidence interval = −2% to +12%, P=0.18).

When donor age was analyzed as a continuous variable using the exact donor age in the analysis, there was not a significant association with graft success during the first 5 years (P=0.15). However, for cases still in follow up at 5 years without prior graft failure, higher donor age was associated with lower graft success after the first 5 years (P<0.001). Results were similar after adjusting for baseline ECD. In exploring this association further across the entire donor age distribution (Figure 3, available at http://aaojournal.org), relatively constant 10-year success rates were observed within three data-derived (not pre-specified) groupings according to donor age (Table 1): 96% (95% confidence interval 89% to 99%) among the 80 study eyes (7% of the 1,090 eyes) that received a cornea from a donor 12 to 33 years old, 75% (95% confidence interval 71% to 78%) among the 880 eyes (81% of the 1,090 eyes) that received a cornea from a donor 34 to 71 years old, and 62% (95% confidence interval 51% to 72%) among the 130 eyes (12% of the 1090 eyes) that received a cornea from a donor 72 to 75 years old. The consistency of success rates from donors age 34 to 71 years can be seen in Figure 4 where this wide age range is stratified into two groupings (34 to 52 and 53 to 71 years). Baseline characteristics were similar in these three donor age groups (Table 2, available at http://aaojournal.org).

Among those with a graft that survived for at least 5 years, the conditional probability of success in the next 5 years was 88% (95% confidence interval = 85% to 91%) in the 12 to 65 years donor age group and 82% (95% confidence interval = 76% to 87%) in the 66 to 75

Ophthalmology. Author manuscript; available in PMC 2014 December 01.
years donor age group. After surviving for 5 years, a graft from a donor 34 to 71 years old had a 86% (95% confidence interval 83% to 89%) probability of success in the next 5 years, while a graft from a donor 72 to 75 years had a 75% (95% confidence interval 62% to 84%) probability of success. In Figure 4, it can be seen that the survival curves appear virtually identical for the first 2 years across the entire donor age range, indicative of a lack of association of donor age with failures during the first 2 years. None of the 74 successful grafts at 2 years from a donor 12 to 33 years failed after the first 2 years. The relative decrease in the success rate with donors 72 to 75 years old relative to the younger donor ages was not observed until after year 6 (Figure 4).

As was observed at 5 years, the success rate when Fuchs’ dystrophy was the indication for transplant was substantially higher than when pseudophakic/aphakic corneal edema was the indication (80% versus 63% at 10 years, P<0.001). Within each of the two diagnostic groups, a similar association between graft success and donor age was seen with a higher success rate with donors 12 to 33 years old and a lower rate with donors 72 to 75 years old (Table 3). The association observed between donor age and graft success was similar across the recipient age range (P value for interaction = 0.86).

Causes of Graft Failure

Causes of graft failure were similar in the 12 to 65 and 66 to 75 years old donor age groups (Table 4). Among 224 eyes with graft failure, 100 (45%) were due to endothelial decompensation, 77 (34%) were due to rejection, 11 (5%) were due to uncorrectable refractive error, 3 (1%) were due to primary donor failure and 33 (15%) were due to other causes listed in Table 4. At least one probable or definite graft rejection episode preceded graft failure in 30 (30%) of the 100 failures attributed to endothelial decompensation. Among the 135 graft failures in the first 5 years, 46 (34%) were due to endothelial decompensation compared with 54 (61%) of the 89 graft failures after 5 years (Table 4 and Table 5, available at http://aaajournal.org). After 5 years, all except 6 of the 89 graft failures (93%) were due to either endothelial decompensation or graft rejection.

DISCUSSION

The CDS was designed to evaluate the effect of donor age on the success of penetrating keratoplasty for corneal disorders due to endothelial disease, mainly Fuchs’ dystrophy and pseudophakic corneal edema. Five-year graft survival data demonstrated identical graft survival rates among recipients who received corneas from donors 66 to 75 years of age compared with those receiving corneas from donors 12 to 65 years of age and an analysis using donor age as a continuous variable did not show a significant association with 5-year graft success. The study was extended to determine whether similar outcomes would be sustained for at least 10 years. As at 5 years, there was not a significant difference comparing the 10-year survival curves of the 12 to 65 and 66 to 75 years old donor age groups. However, in contrast with 5 years, donor age was significantly associated with graft success when exact donor age was analyzed as a continuous variable. Further exploration of the relationship between donor age and graft survival showed that the 10-year success rate was fairly constant over a wide range of donor ages, and differences in success rates were only observed at the lower and upper extremes of the donor age range. Inspection of the data suggested inflection points for differences in success rates at a donor age of 33 years, below which the 10-year success rate was higher and at a donor age of 72 years, above which the 10-year success rate was lower. The lower success rate with donors 72 to 75 years of age relative to the younger donor ages was not apparent until after 6 years of follow up. With the survival curves for all donor ages virtually identical for the first two years, the data demonstrate that there was no association of donor age with early graft failures. As expected, endothelial decompensation was more likely to be the cause of graft failure after 5
years than before 5 years, with prior graft rejection episodes likely contributing in about a third of such cases. The lower graft survival seen at 5 years for pseudophakic corneal edema compared with Fuchs’ dystrophy, irrespective of donor age, was retained in the 10-year data. There was no indication of an interaction between donor age and recipient age on graft survival, meaning that the donor age-graft survival relationship was comparable across the recipient age range. Analysis of the 11-year data provided similar findings to the 10-year data.

There are few previous prospective long-term studies of the effect of donor age on penetrating keratoplasty success. Ing et al\textsuperscript{13} reported a 40% increased risk of graft failure for every 25 years of increasing donor age in a cohort of 394 eyes which included high, intermediate, and low risk cases, with up to 10 years of follow up available for 119 eyes. The Australian Corneal Graft Registry, which includes the full spectrum of high, intermediate, and low risk cases, reported no significant association of donor age with graft failure with follow up ranging from <1 year to 22 years in a 2008 report\textsuperscript{14} although an earlier report did indicate a significant though weak association.\textsuperscript{15}

How will the CDS results impact eye banking and distribution of tissue for corneal transplantation? Available tissue from the extremes of donor age represents a small percentage of the donor pool. In the present study, only 7% of the 1,090 donors were under the age of 34 and only 12% were 72 or older. Most (81%) transplants were performed with a cornea from a donor 34 to 71 years of age, a range over which the graft survival rate was fairly constant. Current Eye Bank Association of America data are fairly similar, in that only 7.9% of corneas procured for transplantation in the U.S. are from donors under the age of 31 and 12.8% are from donors 71 to 80 years of age.\textsuperscript{1} The limited availability of tissue from young donors (<40 years old), for transplantation for endothelial disease, raises the question for corneal surgeons and eye banks as to whether age-matching of donors and recipients is appropriate at the extremes of recipient age, reserving the very youngest donors for the youngest recipients with the greatest life expectancy. With respect to the oldest donors, it is important to note that compared with transplants from donors 34 to 71 years old, transplants from donors 72 to 75 years old had similar survival through 6 years of follow up, and even after 10 years of follow up the difference in survival was modest.

The CDS investigated patients with diagnoses of corneal endothelial disease that placed them at moderate risk for graft failure. Therefore, the results may not apply to patients with a higher likelihood of graft survival such as those with keratoconus or a lower likelihood of survival such as those with failed grafts, chemical burns or densely vascularized corneas. As corneal transplantation has recently shifted to lamellar techniques targeting the diseased stromal or endothelial layer, most of the patients who underwent a penetrating keratoplasty in the CDS likely would undergo some type of endothelial keratoplasty instead today.\textsuperscript{16} Without a prospective clinical trial, one cannot be certain that the findings of this study of penetrating keratoplasty would be the same as those of a study of endothelial keratoplasty. Until such a study is performed, the current study will provide the most useful data to guide eye banks and surgeons in their selection of appropriate corneal tissue for endothelial keratoplasty. Although its primary objective is to evaluate donor cornea preservation time in endothelial keratoplasty, the ongoing Cornea Preservation Time Study funded by the National Eye Institute should provide important data on the effect of donor age on endothelial keratoplasty outcomes.

In summary, the CDS evaluated the effect of donor age on the success of penetrating keratoplasty performed principally for Fuchs’ dystrophy or pseudophakic corneal edema. Although the primary analysis did not show a significant difference in 10-year success rates comparing donor ages 12 to 65 and 66 to 75, there was evidence of a donor age effect at the
very extremes of the age range. Since we observed a fairly constant 10-year success rate for
donor ages 34 to 71 years, which account for approximately 75% of corneas in the United
States available for transplantation, the CDS results indicate that donor age should not be an
important factor in most transplants for endothelial disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support: Supported by cooperative agreements with the National Eye Institute, National Institutes of
Health, Department of Health and Human Services EY12728 and EY12358. Additional support provided by: Eye
Bank, The Cornea Society, Katena Products, Inc., ViroMed Laboratories, Inc., Midwest Eye-Banks (Michigan Eye-
Bank, Illinois Eye-Bank, Cleveland Eye Bank and Lions Eye Bank of New Jersey), Konan Medical Corp., Eye
Bank for Sight Restoration, SightLife, Sight Society of Northeastern New York (Lions Eye Bank of Albany), Lions
Eye Bank of Oregon

References

2013/04/2012_Statistical_Report_FINAL-reduced-size-4-10.pdf
article/view/28.
5. Cornea Donor Study Investigator Group. The effect of donor age on corneal transplantation
18387407]
6. Cornea Donor Study Investigator Group. Donor age and corneal endothelial cell loss five years after
7. Cornea Donor Study Group. Donor age and other factors related to endothelial cell loss ten years
Submitted.
of donor cornea endothelial cell density in the Specular Microscopy Ancillary Study.
10. Cornea Donor Study Group. Clinical profile and early surgical complications in the Cornea Donor
11. Collaborative Corneal Transplantation Studies Research Group. The Collaborative Corneal
Transplantation Studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal
12. Collaborative Corneal Transplantation Studies Research Group. Design and methods of the

Ophthalmology. Author manuscript; available in PMC 2014 December 01.


Figure 1.
Flow-diagram of Subject Participation and Outcome Status for 5- and 10-Year Phases of the Cornea Donor Study (CDS)
Figure 2. Graft Success in Main Donor Age Groups over Time

In panel A, Kaplan-Meier cumulative probabilities of graft survival are shown for the 12 to 65 and 66 to 75 donor age groups. With a log-rank test, the p value comparing the two donor age groups was 0.26. In panel B, the difference in survival probabilities between the 2 donor age groups are shown, with the middle (solid) curve showing the estimated survival difference and the lighter gray curves denoting the lower and upper bounds of the pointwise 95% confidence interval. A positive difference denotes better graft survival with the younger donor age group and vice versa. At 10-years, the difference in survival probabilities between the 2 donor age groups was +6% (95% confidence interval=−1% to +12%). The table beneath panel B presents the number of subjects at risk in the beginning of each year along with the number of graft failures, deaths, lost to follow up and censored subjects during the year.

CI = confidence interval.
Figure 4. Graft Success by 4 Donor Age Groups over Time

In panel A, Kaplan-Meier cumulative probabilities of graft survival are shown for 4 donor age groupings. With a log-rank test, the p value comparing the four donor age groups was <0.001. In panel B, the difference in survival probabilities between eyes receiving a cornea from a donor 12 to 33 years old (N=80) and from a donor 34 to 71 year old (N=880) are shown, with the middle (solid) curve showing the estimated survival difference and the lighter gray curves denoting the lower and upper bounds of the pointwise 95% confidence interval. A positive difference denotes better graft survival with the younger donor age grouping and vice versa. At 10 years, the difference was +22% (95% confidence interval = +16% to +27%). In panel C, the difference in survival probabilities between the eyes receiving a cornea from a donor 34 to 71 years old (N=880) and from 72 to 75 years old
(N=130) are shown, with the middle (solid) curve showing the estimated survival difference and the lighter gray curves denoting the lower and upper bounds of the pointwise 95% confidence interval. A positive difference denotes better graft survival with the younger donor age grouping and vice versa. At 10 years, the difference was +12% (95% confidence interval=+1% to +23%). The table under panel C presents the number of subjects at risk in the beginning of each interval. CI = confidence interval.
Table 1

Graft Survival Rates According to Donor Age

<table>
<thead>
<tr>
<th>Donor Age (years)</th>
<th>N</th>
<th>Graft Failure (N)</th>
<th>10 Year Graft Survival* (Pointwise 95% Confidence Interval)</th>
<th>11 Year Graft Survival* (Pointwise 95% Confidence Interval)</th>
<th>5 Year Graft Survival* (Pointwise 95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>1,090</td>
<td>224</td>
<td>75% (72%, 78%)</td>
<td>73% (69%, 76%)</td>
<td>86% (84%, 88%)</td>
</tr>
<tr>
<td>12 to 65</td>
<td>707</td>
<td>142</td>
<td>77% (73%, 80%)</td>
<td>74% (70%, 78%)</td>
<td>86% (83%, 89%)</td>
</tr>
<tr>
<td>66 to 75</td>
<td>383</td>
<td>82</td>
<td>71% (65%, 76%)</td>
<td>69% (63%, 75%)</td>
<td>86% (82%, 90%)</td>
</tr>
<tr>
<td>12 to 30</td>
<td>69</td>
<td>3</td>
<td>96% (87%, 99%)</td>
<td>96% (87%, 99%)</td>
<td>96% (91%, 100%)</td>
</tr>
<tr>
<td>31 to 40</td>
<td>58</td>
<td>11</td>
<td>78% (63%, 88%)</td>
<td>75% (58%, 85%)</td>
<td>91% (83%, 98%)</td>
</tr>
<tr>
<td>41 to 45</td>
<td>63</td>
<td>11</td>
<td>80% (67%, 89%)</td>
<td>80% (67%, 89%)</td>
<td>80% (70%, 91%)</td>
</tr>
<tr>
<td>46 to 50</td>
<td>68</td>
<td>11</td>
<td>81% (68%, 90%)</td>
<td>78% (62%, 87%)</td>
<td>92% (86%, 99%)</td>
</tr>
<tr>
<td>51 to 55</td>
<td>126</td>
<td>34</td>
<td>72% (62%, 80%)</td>
<td>65% (54%, 74%)</td>
<td>80% (73%, 87%)</td>
</tr>
<tr>
<td>56 to 60</td>
<td>152</td>
<td>20</td>
<td>76% (67%, 83%)</td>
<td>76% (67%, 83%)</td>
<td>87% (82%, 93%)</td>
</tr>
<tr>
<td>61 to 65</td>
<td>171</td>
<td>43</td>
<td>70% (62%, 77%)</td>
<td>69% (60%, 76%)</td>
<td>84% (79%, 90%)</td>
</tr>
<tr>
<td>66 to 70</td>
<td>217</td>
<td>40</td>
<td>75% (67%, 81%)</td>
<td>75% (67%, 81%)</td>
<td>87% (82%, 92%)</td>
</tr>
<tr>
<td>71 to 75</td>
<td>166</td>
<td>36</td>
<td>66% (56%, 74%)</td>
<td>62% (51%, 71%)</td>
<td>85% (79%, 91%)</td>
</tr>
<tr>
<td>12 to 33</td>
<td>80</td>
<td>3</td>
<td>96% (89%, 99%)</td>
<td>96% (89%, 99%)</td>
<td>96% (92%, 100%)</td>
</tr>
<tr>
<td>34 to 71</td>
<td>880</td>
<td>185</td>
<td>75% (71%, 78%)</td>
<td>72% (68%, 76%)</td>
<td>86% (83%, 88%)</td>
</tr>
<tr>
<td>72 to 75</td>
<td>130</td>
<td>36</td>
<td>62% (51%, 72%)</td>
<td>62% (51%, 72%)</td>
<td>82% (74%, 89%)</td>
</tr>
</tbody>
</table>

* Kaplan-Meier estimates
Table 3

Graft Survival at 5, 10, and 11 Years by Baseline Diagnosis and Donor Age Groups

<table>
<thead>
<tr>
<th></th>
<th>Fuchs Dystrophy</th>
<th>Pseudophakic/Aphakic Corneal Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Graft Survival Estimates* (95% Confidence Interval)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>5 Years</td>
<td>10 Years</td>
</tr>
<tr>
<td></td>
<td>576</td>
<td>676</td>
</tr>
<tr>
<td></td>
<td>369</td>
<td>369</td>
</tr>
<tr>
<td>Donor age 12 to 33 years</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Donor age 34 to 71 years</td>
<td>93% (90%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 72 to 75 years</td>
<td>88% (81%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 34 to 71 years</td>
<td>93% (90%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 72 to 75 years</td>
<td>88% (81%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 12 to 33 years</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Donor age 34 to 71 years</td>
<td>93% (90%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 72 to 75 years</td>
<td>88% (81%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 34 to 71 years</td>
<td>93% (90%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
<tr>
<td>Donor age 72 to 75 years</td>
<td>88% (81%, 95%)</td>
<td>80% (76%, 84%)</td>
</tr>
</tbody>
</table>

* Kaplan-Meier estimates and pointwise 95% confidence interval
Table 4

Causes of Graft Failure

<table>
<thead>
<tr>
<th></th>
<th>Total Graft Failures (N=224)</th>
<th>Graft Failures 0–5 years after surgery (N=135)</th>
<th>Graft failures &gt;5 years to end of study (N=89)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Donor Age Group</td>
<td>Donor Age Group</td>
<td>Donor Age Group</td>
</tr>
<tr>
<td></td>
<td>12 to 65</td>
<td>66 to 75</td>
<td>12 to 65</td>
</tr>
<tr>
<td>Number of Patients</td>
<td>707</td>
<td>383</td>
<td>707</td>
</tr>
<tr>
<td>Total Graft Failures</td>
<td>142</td>
<td>82</td>
<td>90</td>
</tr>
<tr>
<td>Primary Donor Failure</td>
<td>3 (2%)</td>
<td>0</td>
<td>3 (3%)</td>
</tr>
<tr>
<td>Refractive</td>
<td>7 (5%)</td>
<td>4 (5%)</td>
<td>5 (6%)</td>
</tr>
<tr>
<td>Graft Rejection</td>
<td>50 (35%)</td>
<td>27 (33%)</td>
<td>32 (36%)</td>
</tr>
<tr>
<td>Non-rejection</td>
<td>82 (58%)</td>
<td>51 (62%)</td>
<td>50 (56%)</td>
</tr>
</tbody>
</table>

Causes of Non-rejection Graft Failure:

<table>
<thead>
<tr>
<th></th>
<th>12 to 65</th>
<th>66 to 75</th>
<th>12 to 65</th>
<th>66 to 75</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endothelial decompensation</td>
<td>61 (43%)</td>
<td>39 (48%)</td>
<td>30 (33%)</td>
<td>16 (36%)</td>
</tr>
<tr>
<td>Signs of definite/probable rejection prior to failure</td>
<td>17</td>
<td>13</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>No signs of definite/probable rejection prior to failure</td>
<td>44</td>
<td>26</td>
<td>24</td>
<td>10</td>
</tr>
<tr>
<td>Infection</td>
<td>12 (8%)</td>
<td>5 (6%)</td>
<td>11 (12%)</td>
<td>4 (9%)</td>
</tr>
<tr>
<td>Epithelial defects</td>
<td>3 (2%)</td>
<td>3 (4%)</td>
<td>3 (3%)</td>
<td>3 (7%)</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>2 (1%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Epithelial downgrowth</td>
<td>2 (1%)</td>
<td>0</td>
<td>2 (2%)</td>
<td>0</td>
</tr>
<tr>
<td>Graft failure following retinal detachment repair</td>
<td>0</td>
<td>1 (1%)</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Corneal thinning</td>
<td>1 (&lt;1%)</td>
<td>0</td>
<td>1 (1%)</td>
<td>0</td>
</tr>
<tr>
<td>Hypotony</td>
<td>1 (&lt;1%)</td>
<td>0</td>
<td>1 (1%)</td>
<td>0</td>
</tr>
<tr>
<td>Wound dehiscence</td>
<td>0</td>
<td>1 (1%)</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
</tbody>
</table>

*Number in follow up after 5 years without graft failure in the first 5 years.